• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Jannsen and Nanolek are launching a project for localization of Darzalex®

22.10.2019/in News /by Evgeniy Makarevich

Janssen, a pharmaceutical company owned by Johnson and Johnson, and a Russian biopharmaceutical company Nanolek have announced the localization of manufacturing of Darzalex®(daratumumab) in Russia, which is used in treatment of multiple myeloma.

The battle against malignant hematologic diseases has been a strategic direction that Janssen had been working towards for many years now. Our team is diligently working on the search of new molecules, marketing and increasing access to therapy for such debilitating and hard to treat disease as multiple myeloma. This year our innovative product daratumumab was included in a program of high cost nosologies, which gives hope to many patients around the country. In support of this important milestone, we would like to express our commitment to the local Russian strategy, and are delighted to announce a partnership in localization of Darzalex®with one of the progressive Russian producers- biopharmaceutical company Nanolek. We believe that this collaboration will lead to a higher availability of this innovative therapy to Russian patients”, stated Katerina Pogodina, Managing Director of “Janssen” Russia and CIS, Executive Director of “Johnson and Johnson”.

Darzalex®localization is planned at the site of “Nanolek” biomedical center, which is located in Kirovskaya Oblast, in compliance with GMP and ISO.

Vladimir Khrestenko,” Nanolek” president commented: “Today we can talk about global innovations and enormous reserves for extending the life expectancy of the population in terms of availability of treatment for oncologic diseases. Our partnership with Janssen has a large social significance: by joining forces, we can positively contribute to the life of Russian patients living with malignant blood diseases. Our joint localization project will widen the access of patients with multiple myeloma to modern and effective therapy. I’m glad that this collaboration will help to solve one of the most complex medical problems, and aid in improving life expectancy and quality of life of Russian patients”.

Both oncological and vaccination areas are of the primary focus for Nanolek at the moment. The company is actively developing its medication database for treatment of oncological diseases both in collaboration with international companies, and on their own.

In 2017, Darzalex®was registered in Russia and marketed as a monotherapy treatment in patients with relapsing or refractory multiple myeloma. Previous treatment included proteasome inhibitors and immunomodulating substances. In 2019 the drug had a new indication added to its description.

Now, Darzalex® is also recommended as a combination therapy for treatment of adult patients with multiple myeloma. Daratumumab is the first human monoclonal antibody to CD38 protein that has been approved for treating this disease.

Janssen has been contributing to the fight against malignant blood diseases in Russia for over 10 years, by studying molecular and cellular mechanisms of disease development, and by producing and marketing innovative drugs. In 2007, Janssen has made a breakthrough in treatment of multiple myeloma, and the Darzalex® which has appeared on the Russian market in 2017 was acknowledged to be a breakthrough therapy by worldwide regulatory agencies.

Link: gmpnews.ru

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 3 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Sсientists at Moscow State University (MSU) a new treatment for sepsis FDA approved a new breakthrough therapy for Cystic Fibrosis
Scroll to top